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Abstract
A dynamic model of STAT1 degradation by the V protein of parainfluenza virus 5 (PIV5; formerly SV5) has been proposed. In it, the V protein
functions as a bipartite adaptor linking DDB1, a component of a cellular SCF-like ubiquitin E3 ligase complex, to STAT2, which in turn binds STAT1
and presents STAT1 to the E3 ligase complex for ubiquitination and subsequent degradation. Furthermore, it appears that loss of STAT1 from the
complex results in decreased affinity of V for STAT2 such that STAT2 either dissociates from V or is displaced by STAT1/STAT2 complexes,
facilitating the cycling of the DDB1/PIV5 V containing E3 complex for further rounds of STAT1 ubiquitination and degradation. By determining the
approximate number of molecules of V, DDB1, STAT1 and STAT2 present in IFN-treated 2fTGH cells, we provide additional evidence for this
dynamicmodel of STAT1degradation. These results show that (i) in IFN-treated cells there is approximately 4-fold less STAT2 and 15-fold lessDDB1
than STAT1 per cell and thus DDB1 and STAT2must repeatedly acquire more STAT1 for degradation to go to completion, and (ii) approximately 600
molecules of V protein per cell can target as many as 120,000 molecules of STAT1 for degradation in the absence of either viral or cellular protein
synthesis. The importance of this mechanism in terms of the ability of the virus to dismantle the IFN-induced anti-viral state of cells is discussed.
© 2007 Elsevier Inc. All rights reserved.Keywords: STAT; Interferon; DDB1; IFN-induced anti-viral state; PIV5; SV5Introduction
Cells of all tissues react to viral infection by activating sig-
nalling cascades that lead to the induction of type I IFN (IFN-
α/β). The consequence of secreted IFN-α/β binding to
appropriate cell surface receptors on neighboring cells is the
induction of another intracellular signalling cascade via the JAK/
STAT pathway (Levy and Darnell, 2002; Stark et al., 1998). In
this pathway, STAT1 and STAT2 are activated by phosphoryla-
tion, form heterodimers and associate with IRF-9 to form a
heterotrimer, termed IFN-stimulated gene factor 3 (ISGF3).
ISGF3 translocates to the nucleus and induces the transcription
of genes that specify the so-called anti-viral state. Many of the
up-regulated proteins, for example, 2′5′ oligoadenylate synthe-
tase (OAS) MxA and protein kinase R (PKR) inhibit viral⁎ Corresponding author. School of Biology, University of St. Andrews, Fife
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doi:10.1016/j.virol.2007.06.024replication and in general the cellular status is unfavourable to
viral replication (Goodbourn et al., 2000; Haller et al., 2006).
In the case of parainfluenza virus type 5 (PIV5; formerly
known as SV5) it is known that cells in an IFN-induced anti-viral
state suppress virus replication by altering the pattern of virus
transcription and protein synthesis, although it appears that these
effects are not mediated through PKR, OAS or MxA (Carlos et
al., 2005, 2007). However PIV5, like most other paramyx-
oviruses, at least partially circumvents the IFN response by
blocking IFN signalling and limiting IFN production (for re-
views see Conzelmann, 2005; Garcia-Sastre, 2004; Horvath,
2004; Nagai and Kato, 2004; Stock et al., 2004). PIV5 blocks
IFN signalling by targeting STAT1 for ubiquitination and
subsequent degradation by the proteasome (Didcock et al., 1999;
Precious et al., 2005b). This process is mediated solely by the
viral V protein (Andrejeva et al., 2002b; Didcock et al., 1999;
Parisien et al., 2002; Precious et al., 2005b). The V protein is a
structural component of the virion, it is 222 amino acids long and
is translated from mRNA produced as a faithful transcript of the
Fig. 1. Estimates of the numbers of molecules of DDB1, STAT1 and STAT2 in
untreated and IFN-treated 2fTGH cells. (A) Immunoblot of 2fTGH cells (1×105/
well) treated or untreated with IFN for 16 h and in vitro L-[35S]methionine-
labelled standards to compare the relative levels of DDB1, STAT2 and STAT1.
Panel B shows the calculated number of molecules/cell of the respective proteins
(the approximate mean of 3 independent experiments).
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shown that V facilitates the degradation of STAT1 by acting as a
bipartite adaptor molecule linking cellular E3 ubiquitin ligase
complexes (consisting of the 127 kDa subunit of the UV
damaged DNA binding protein (DDB1), Cullin 4, and RBX)
with STAT2/STAT1 complexes, formed independently of IFN-
induced phosphorylation (Andrejeva et al., 2002a; Parisien et al.,
2002; Precious et al., 2005a, 2005b; Ulane and Horvath, 2002;
Ulane et al., 2005). Recently, we proposed a model for the
ubiquitination of STAT1 whereby the STAT2/STAT1 complex is
brought to the DDB1/Cullin 4/RBX ubiquitin E3 ligase complex
by the simultaneous interaction of V protein with both STAT2
and DDB1 (Precious et al., 2005a). STAT1 is held in place on the
DDB1/Cullin 4/RBX ubiquitin E3 ligase by both the viral V
protein and by STAT2 with no direct interaction between Vand
STAT1 (Precious et al., 2005a, 2005b). This complex is stable
only whilst DDB1, V, STAT2 and STAT1 are associated. Loss or
absence of STAT1 causes STAT2 to dissociate from the V
protein, which probably remains bound to DDB1. An alternative
model has been proposed in which the V protein oligomerises to
form spherical particles that act as scaffolds for E3 ubiquitin
ligase activity (Ulane et al., 2005). However, recent X-ray
crystallography data for the DDB1/Cullin 4/RBX/V complex
(Angers et al., 2006; Li et al., 2006a) have added details of the
spatial relationships of the E3/V complex and strongly support
the model in which monomeric V binds both DDB1 and STAT2.
In this report we provide further evidence for a dynamic model
of STAT1 degradation by demonstrating that V can act in a
catalytic manner to target an excess of STAT1 for degradation
and discuss how this mechanism of action allows the virus to
dismantle the IFN-induced anti-viral state of cells.
Results
Degradation of STAT1 under conditions in which it is in excess
over the PIV5 V protein
To determine whether the V protein of PIV5 can act
catalytically in the turnover of STAT1 we wished to monitor the
degradation of STAT1 under conditions where STAT1 was
likely to be in excess over the V protein. Additionally, we
wished to monitor intracellular levels of those specific cellular
proteins that make up the previously described core degradation
complex. To establish the cellular levels of specific proteins,
extracts were analysed by immunoblotting and compared to
standards of known amounts of the test protein. Protein
standards were prepared using in vitro translation and
incorporation of L-[35S] methionine of defined specific activity
(see Materials and methods).
Our estimates show that 2fTGH cells contain approximately
8000 molecules of STAT1, 10,000 molecules of STAT2 and
8000 molecules of DDB1 prior to IFN treatment (Fig. 1). After
treatment with IFN, STAT1 levels were substantially higher at
approximately 120,000 molecules/cell, STAT2 levels increased
to 30,000 molecules/cell whilst DDB1 levels remained
substantially unchanged. Upon infection with PIV5, V protein
levels were calculated to be approximately 4000 molecules/cell at an moi of 50, and 400 to 600 molecules/cell at an moi
of 5.
We next monitored the levels of cellular proteins subsequent to
infection by PIV5. In order to ensure that only the fate of pre-
existing proteins were monitored we carried out infections in the
presence of cycloheximide, an inhibitor of protein synthesis. A
typical immunoblot of a time course experiment is shown in Fig. 2
(note that because each component is detected with a different
antibody the relative intensities of STAT1, STAT2, DDB1 and V
can only be compared to themselves and not to each other, i.e. the
relative intensity of STAT1 compared to PIV5 V does not reflect
their relative concentration within the cell). In the presence of
cycloheximide, over a 24 h time period, in uninfected cells there
was a slight reduction in the amount of STAT2, but the levels of
DDB1 and STAT1 remained relatively constant (Fig. 2A).
Strikingly, at an input multiplicity of 50 pfu per cell (approxi-
mately 4000 molecules of V per cell), PIV5 targeted all the
detectable STAT1 for degradation between 8 and 12 h p.i. in the
absence of virus protein synthesis. In contrast, the levels of DDB1
and STAT2 were not significantly altered under these conditions
(Fig. 2B). In a parallel experiment, at a multiplicity of 5 pfu/cell
(400–600 molecules of V per cell), all the STAT1 was degraded
by 24 h p.i. (Fig. 2C). Fig. 3 shows graphically the calculated
number of molecules of PIV5 V, STAT1, STAT2 and DDB1
averaged from 3 individual experiments as shown in Fig. 2. As an
additional control in these experiments, we also examined the
relative levels of STAT1, STAT2 and DDB1 in cells infected with
Mapuera virus, a rubulavirus that blocks IFN signalling by
sequestering STAT1 and STAT2 rather than targeting them for
degradation (Hagmaier et al., 2007). As expected, under these
same conditions, at a multiplicity of 50 pfu/cell, there was no
obvious change in the relative levels of these proteins compared to
Fig. 2. Time course of PIV5 induced STAT1 degradation in IFN-pretreated 2fTGH cells in the absence of viral or cellular protein synthesis. Monolayers of 2fTGH cells
were pretreated with IFN for 16 h and either mock infected (A) or infected with PIV5 at moi 50 (B) and 5 (C) and cultured, from the time of infection, in the presence of
cycloheximide. Total cell extracts were made at the time points indicated and quantitative immunoblot analysis was used to compare the amounts of DDB1, STAT2,
STAT1 and V proteins in 1×105 cell equivalents to in vitro metabolically labelled L-[35S]methionine standards.
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that PIV5 V must act catalytically since 120,000 molecules of
STAT1 are degraded by 400–600 molecules of V in a period of 24
h. Furthermore, the data also show that since the number of DDB1
and STAT2 molecules is less than STAT1 they must also act
catalytically in the degradation process.
Catalytic degradation of STAT1 allows PIV5 to dismantle the
IFN-induced anti-viral state of cells
Having established that PIV5 can target all the STAT1 in IFN-
pretreated cells for degradation, we next examined the con-
sequences of this in terms of the ability of the virus to dismantle a
pre-existing IFN-induced anti-viral state in cells. In these
experiments, Vero cells, which cannot produce, but can respond
to IFN, were used. These cells were treated or mock-treated with
IFN prior to infection with either the CPI+ or CPI− isolates of
PIV5. CPI− was derived from CPI+ but, unlike CPI+, it cannot
target STAT1 for degradation because three amino acid
substitutions in its V protein make it non-functional for STAT1degradation (Chatziandreou et al., 2002). In these experiments,
following infection of the IFN-pretreated cells, the cells were
cultured in the presence or absence of IFN. To monitor the state
of IFN-induced effects on virus protein synthesis, cells were
labelled for 1 h with L-[35S]methionine at various times post-
infection and newly synthesised virus proteins visualised by
immunoprecipitation. Unsurprisingly, these results (Fig. 4)
showed significantly less virus protein synthesis in IFN-pre-
treated cells compared to untreated cells. Furthermore, the rela-
tive amounts of the different virus proteins synthesised in IFN-
pretreated cells were altered such that more NP and P proteins
were made compared to M, HN or L proteins. These results also
confirmed that CPI− (which cannot direct the degradation of
STAT1 or block IFN signalling) could not dismantle the IFN-
induced anti-viral state. In contrast CPI+ was capable of dis-
mantling the IFN-induced anti-viral state. Thus, when CPI+
infected IFN-pretreated cells were cultured in the presence of
IFN, an increase in the levels of expression of NP was clearly
observed at 18 h p.i. and expression of HN, M and L could be
detected by 24 h p.i.
Fig. 3. Graphic display of the calculated number of molecules per cell of DDB1, STAT1, STAT2 and PIV5 V proteins during a time course of PIV5-induced STAT1
degradation in IFN-pretreated 2fTGH cells in the absence of viral or cellular protein synthesis. The graph shows the mean number of molecules per cell of DDB1,
STAT1, STAT2 and PIV5 V from 3 independent experiments (the error bars represent the standard deviation from these independent experiments not replicates of one
experiment) of time courses of infection in which IFN-pretreated 2fTGH cells were mock infected or infected with PIV5 (at moi of 50 or 5) or with Mapuera virus
(moi 50). Note that the amount of Mapuera V protein was not estimated due to the lack of a suitable antibody.
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cells infected with CPI−, CPI+ and Mapuera virus. With regard
CPI+ and CPI−, these results supported the conclusion drawn
from the immune precipitation studies, namely that CPI+, but
not CPI−, can dismantle an IFN-induced anti-viral state if
cultured in the presence of IFN. Thus, at all time points
examined, in the continuous presence of IFN there was N100-
fold reduction in the amount of infectious virus released from
CPI− infected cells. However, if the IFN was removed at the
time of infection, the yield of infectious CPI− virus increased
significantly by 42 h p.i. (Fig. 5A). In contrast, whilst
pretreatment of cells with IFN also initially significantly reduced
the amount of infectious virus released from CPI+ infected
cultures, there was an obvious increase in amount of infectious
virus by 42 h p.i., regardless of whether or not IFN was removed
at the time of infection (Fig. 5B). Interestingly, although
Mapuera blocks IFN signalling, under these conditions,
Mapuera virus did not appear to be able to dismantle the IFN-
induced anti-viral state. Thus, although there was an increase inthe yield of Mapuera virus if IFN was removed at the time of
infection, no such increase was observed if the cells were
incubated in the continuous presence of IFN (Fig. 5C).
Discussion
The main conclusion from these studies is that the V protein
of PIV5 acts catalytically in the degradation of STAT1 and that
this mechanism enables the virus to dismantle an IFN-induced
anti-viral state in cells. Thus 400 to 600 molecules of V were
capable of inducing the degradation of 120,000 molecules of
STAT1 within a 24 h period. Furthermore, under these
conditions, STAT2 and DDB1 levels remained relatively stable
and therefore must also be recycled for all the STAT1 to be
degraded. In IFN-treated 2fTGH cells molecular ratio of STAT1:
STAT2:DDB1 is approximately 15:4:1. These numbers also
mean that if the number of V molecules becomes greater than
DDB1 molecules (which will happen during an infectious cycle
if cellular protein synthesis is not blocked), then the rate of
Fig. 4. Effects of IFN pretreatment on CPI− and CPI+ protein synthesis in Vero cells. Monolayers of Vero cells were either untreated or pretreated with IFN for 16 h
prior to infection with moi 50 pfu/cell of either PIV5 CPI+ or CPI− virus. At the time of infection half of the pretreated cells had the IFN removed and were cultured in
the absence of IFN for the remainder of the experiment. The other half of the IFN-pretreated cells were cultured continuously with IFN throughout the experiment. At
the times indicated cells were metabolically labelled with L-[35S]methionine for 1 h. Virus proteins were immunoprecipitated using a mixture of antibodies specific to
NP, P, M, HN and L proteins, separated on 4–12% gradient PAG and visualised by phosphoimager analysis. Bottom of figure: immunoblot analysis was used to detect
the levels of STAT1 in samples of corresponding total cell extracts.
Fig. 5. Effect of IFN pretreatment, and subsequent release from IFN treatment, on the production of infectious CPI−, CPI+ andMapuera virus from infected Vero cells.
Monolayers of Vero cells were either untreated (UNT) or pretreated with IFN for 16 h prior to infection with CPI+, CPI− or Mapuera viruses (moi of 50 pfu/cell). At the
time of infection half of the pretreated cells had the IFN removed and were cultured in the absence of IFN for the remainder of the experiment (PRET− IFN). The other
half of the IFN-pretreated cells were cultured continuously with IFN throughout the experiment (PRET+IFN). At the times indicated the culture mediumwas collected
and the amount of infectious virus determined by plaque assays.
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the cellular components of the ubiquitin E3 ligase. These results
also support our dynamicmodel for STAT1 degradation in which
V forms a stable interaction with DDB1 in the E3 ligase com-
plex, and where the ultimate ubiquitination and loss of STAT1
from the degradation complex destabilises the interaction of V
with STAT2. This leads to either STAT2 dissociating from the
complex or being displaced by STAT1/2 complexes, thereby
ensuring recycling of the components of the degradation com-
plex and the catalytic degradation of STAT1 (Precious et al.,
2005a).
Results on the replication of PIV5 in IFN-pretreated cells
confirmed that PIV5 replication is severely impaired in cells that
are in an IFN-induced anti-viral state (Carlos et al., 2005).
Additionally, they show that upon removal of IFN it takes more
than 24 h for the cells to go out of the anti-viral state and for CPI−
(which does not block IFN signalling) replication to recover
such that a normal pattern of protein synthesis is established.
Furthermore, the results show that continued IFN signalling is
required for cells to maintain their anti-viral state, and that if the
virus fails to target STAT1 for degradation then, in the con-
tinuous presence of IFN, normal patterns of replication are never
established. If, on the other hand, the infecting virus targets
STAT1 for degradation (CPI+), normal virus replication
recovers more quickly (whether or not IFN is removed from
the culture medium), and the virus can dismantle the anti-viral
state.
As discussed, the targeted degradation of STAT1 by the V
protein of PIV5 is a complex molecular process in which the V
protein acts as a bridge between a cellular DDB1-containing E3
ligase complex and STAT1/2 heterodimers. PIV5 V binds to
DDB1 by inserting an entire amino terminal α-helix into a
pocket in the DDB1 structure and is predicted to bind STAT2 by
assembling a binding site from both the amino and carboxy
terminal domains of the protein (Angers et al., 2006; Li et al.,
2006b). However, not all paramyxoviruses have such a com-
plicated mechanism of blocking IFN signalling and many, in-
cluding Mapuera virus, simply sequester STAT1 and/or STAT2
into inactive complexes (Hagmaier et al., 2007). In contrast to
PIV5 V, Mapuera virus V protein is unable to bind to DDB1 and
lacks sequence homology in the amino terminal domain
predicted to be part of the STAT2 binding site, suggesting that
interaction with STAT2 occurs via a different mechanism. How
these different strategies for blocking IFN signalling have arisen
remains unknown, but the consequences appear to be that under
some conditions viruses which target STATs for degradation
may be better able to dismantle an IFN-induced anti-viral state
than viruses which sequester STATs. Indeed, in order to block
IFN signalling viruses which sequester STATsmust synthesise at
least as many V molecules as STAT molecules (and possibly
significantly more). For example, Mapuera virus would need to
synthesise more than 120,000 molecules of V to sequester all the
STAT1 in IFN-treated 2fTGH cells. Furthermore, the fact that
Mapuera failed to overcome the IFN-induced anti-viral state
suggests that under some conditions Mapuera virus may not be
able to block IFN signalling by sequestering all the STAT1.
Similarly, it has been suggested that, whilst recombinant Sendaiviruses that simply sequester STAT1 may be able to prevent the
establishment of an IFN-induced anti-viral state, wild type
Sendai virus must degrade STAT1 to dismantle a pre-existing
anti-viral state in cells (Garcin et al., 2002). Nevertheless,
viruses that simply sequester STATs must have evolved different
strategies and lifestyles to overcome this problem. Indeed, the
very different ways viruses interact with the IFN system must
influence their biology, the way they replicate and the types of
diseases they cause.
Materials and methods
Cells and viruses
2fTGH cells (a cloned derivative of the cell line HGRPT−
HT1080 containing a selectable IFN-regulated marker) (Pelle-
grini et al., 1989) and African green monkey kidney cells (Vero)
were propagated in Dulbecco’s modified medium (DMEM)
supplemented with 10% foetal bovine serum at 37 °C. PIV5
virus strains W3a, CPI+ and CPI− were grown and titrated as
described previously and shown to have a titre of 3×108 pfu/ml
for W3a and CPI+, 2×108 pfu/ml for CPI−. Mapuera virus was
grown as described previously and had a titre of 108 pfu/ml.
Virus infection
For immunoblot analysis
2fTGH were seeded onto 50 mm culture dishes and grown to
a density of approximately 2–3×106 cells/dish. Where appro-
priate, cells were treated for 16 h with 1000 units/ml rHuIFN-
αA/D (Cat. No. 11200-2 PBL Biomedical Laboratories), or left
untreated. Cells were then washed 3 times with warm medium
and incubated for 1 h at 37 °C in medium containing 50 μg/ml
cycloheximide prior to either mock infection or infection at
multiplicities of either 5 or 50 pfu/cell of PIV5 in 1ml serum-free
DMEM (all subsequent washes and incubation media contained
cycloheximide at the same concentration). After infection for 1 h
at 37 °C the virus was removed and the cells washed 3 times and
incubated at 37 °C in DMEM containing 10% foetal bovine
serum. At various time points cells were washed 3 times in ice-
cold phosphate buffered saline (PBS), drained, and resuspended
in SDS PAGE lysis buffer to give a cellular concentration equi-
valent to 107/ml. After sonication, 10 μl of whole-cell extract
was separated on 4–12% Novex PAG as described previously
(Precious et al., 2005b) before being transferred to PVDF for
subsequent immunoblot analysis.
For metabolic radiolabelling/plaque assays
Monolayers of Vero cells in 75 cm2 flasks containing
approximately 3×106 cells were pretreated for 16 h with 1000
units/ml rHuIFN-αA/D, or left untreated followed by infection
for 1 h at 37 °C with either PIV5 CPI+ or CPI− virus at a moi of
50 or 5. Following infection, half of the IFN-treated monolayers
had the IFN removed, whilst the remainder were incubated in the
continued presence of IFN until the end of the experiment. At
various time points after infection, IFN cells were metabolically
labelled for 1 h with L-[35S]methionine (37 TBq/mmol; GE
120 B.L. Precious et al. / Virology 368 (2007) 114–121Healthcare) inmethionine-free tissue culture medium.At the end
of the labelling interval, cells were washed twice in ice-cold
phosphate buffered saline (PBS) and lysed in immunoprecipita-
tion buffer (10 mM Tris–HCl, pH 7.8, 5 mM EDTA, 0.3%
Nonidet P-40 and 0.65 M NaCl; 4×106 to 6×106 cells/ml
buffer) by sonication with an ultrasonic probe. Soluble antigen
extract was prepared by subjecting the cell lysate to centrifuga-
tion at 12,000×g for 1 h to remove particulate material. Immune
complexes were formed by incubating 1 ml samples of the
soluble antigen extracts with a pool of specific antibodies to the
NP, P, M, HN and L proteins of PIV5. The media from the cells
above were kept from each time point and used in a plaque assay.
L-[35S]methionine in vitro labelling
L-[35S]methionine-labelled proteins were synthesised indivi-
dually in the ‘Quick prime’ Reticulocyte lysate system
(Promega) following the manufacturers’ instructions using
plasmid constructs for DDB1, STAT1, STAT2 and PIV5 V as
previously described (Precious et al., 2005b) and L-[35S]
methionine with a specific activity of 37 TBq/mmol. Labelled
proteins were separated, alongside the corresponding cell
extracts described above, by SDS PAGE and transferred to
PVDF paper for immunoblot analysis (as described below). The
concentration of endogenous methionine in the reticulocyte
lysate mixture was determined by comparing the derived density
of an immunoblot of STAT2 (see below) with a phosphoimager
derived density of the L-[35S]methionine-labelled STAT2 in
samples prepared from lysates to which unlabelled methionine
had or had not been added to a concentration of 10 μM and
100 μM. The concentration of the added L-[35S]methionine was
1 μM per reaction and thus the actual specific activity of L-[35S]
methionine in the reticulocyte lysate mix could be determined.
Results from these analyses indicated that the concentration of
endogenous methionine was also approximately 1 μM and thus
the specific activity of the L-[35S]methionine in the reticulocyte
lysate was 18.5 TBq/mmol.
Immunoblotting, scintillation counting and determination of
cellular protein levels
After transfer of PAG samples to PVDF as described above,
DDB1, STAT1, STAT2 and PIV5 V were detected individually
using anti-DDB1 antibody (Transduction laboratories Cat No
BD 612489) anti-STAT1 and STAT2 antibodies (Santa Cruz Cat.
No. sc8557 and sc476 respectively) and PIV5 V using PIV5 PK
antibody described previously. Protein/antibody interactions
were visualised using appropriate horseradish peroxidase-con-
jugated secondary antibodies and enhanced chemiluminescence
reagents (ECL Plus GE Healthcare) using a Fuji LAS 1000
digital camera system insensitive to radionuclide emissions. The
density of the bands was quantified using Image Gauge software
(Fuji). All blots were exposed for 1 min and 5 min and the
relative densities of all bands of interest calculated. Any
significant variance between the lower and higher exposure of
the immunoblots, after correcting for time, that may have
suggested ECL reagent exhaustion or over exposure resulted in
those filters being discarded and the whole sample series run
again with lower initial sample loads until the 1 and 5 minexposures were correlated. The L-[35S]methionine-labelled pro-
teins were excised from the blot and counted using a Beckman
6000SC scintillation counter. To determine the accuracy of the
results and to account for any quenching, 5 kBq spots of L-[35S]
methionine (minimum of 5 samples per experiment) were also
counted as positive controls. Negative controls were similarly
sized excisions from non-radioactive areas of the immunoblots.
Scintillation counts, after correction for efficiency, were used to
determine the incorporated Bq value and hence, having
accounted for the number of methionine residues per protein
and the concentration of endogenous methionine in the
reticulocyte lysate (see above), the number of moles of each
labelled protein. From these data, the immunoblot densities and
number of 2fTGH cell equivalents per PAG slot (1×105), the
numbers of molecules of each protein per cell were determined.References
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